Did GSK settle with anyone other than Apotex? If not, GSK may continue to detail branded Lovaza until the CoM patent expires.
In any case, I don't think GSK is interested in Vascepa or AMRN, although they would like to see Vascepa get NCE status for the reason mentioned in my previous post.
Market Data 
Markets 
AI
